| Health / Medical Topics |
GP2 Peptide/GM-CSF Vaccine
A vaccine containing a HER2/Neu-derived epitope (amino acids 654-662) (GP2), and combined with granulocyte-macrophage colony-stimulating factor (GM-CSF), with potential antineoplastic and immunoadjuvant activity. Upon vaccination, GP2 may activate the immune system to mount a cytotoxic T-lymphocyte (CTL) immune response against HER2/Neu expressing cancer cells. GM-CSF may potentiate a tumor-specific cytotoxic T-lymphocyte (CTL) response against cancer cells expressing the HER2/Neu antigen. HER2/neu, a tumor associated antigen (TAA), is overexpressed in a variety of tumor cell types and is highly immunogenic. (NCI Thesaurus)
YOU MAY ALSO LIKE
A synthetic peptide consisting of amino acid residues 614 through 622 of the melanoma-melanocyte antigen glycoprotein 100 (gp100). Vaccination with gp100:614-622 peptide…
A synthetic peptide vaccine consisting of the amino acids 44 through 59 of the glycoprotein 100 (gp100) melanoma antigen. Vaccination with…
A peptide vaccine consisting of the amino acids 280 through 288 of the melanoma antigen glycoprotein 100 (gp100) with potential antineoplastic…
A vaccine consisting of the amino acids 280 through 288 of the melanoma antigen glycoprotein 100 (gp100) with potential antineoplastic activity. …
A synthetic peptide cancer vaccine consisting of amino acid residues 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen, with a…
A synthetic peptide vaccine consisting of the amino acids 209 through 217 of the glycoprotein 100 (gp100) melanoma antigen. Vaccination with…
